Search
An Early-Stage Type 1 Diabetes (T1D) Clinic aims to revolutionise diabetes care and support families navigating the beginning of an early-stage T1D diagnosis.
The generous support of Western Australians through Channel 7’s Telethon is helping to fund life-changing child health research, with two The Kids Research Institute Australia researchers awarded significant grants.
Children’s Diabetes Centre researchers at The Kids Research Institute Australia are among the big winners of prestigious Raine Medical Research Foundation Awards.
"This system definitely helped with my diabetes management, especially overnight, and helped to keep my blood sugars as stable as possible which was fantastic,"
The study involved screening young people to learn more about the development of long-term kidney, eye and cardiovascular complications in adolescents with T1D.
The Children’s Diabetes Centre at The Kids Research Institute Australia is leading the longest and largest at-home trial of a hybrid closed-loop insulin pump system.
Continuous glucose monitoring systems are used in therapeutic decisions for diabetes management, however, the impact of body composition on CGM accuracy is not known. Body composition variables were collected in an observational study designed to determine the accuracy of an investigational Medtronic Guardian™ sensor 3.
To evaluate real-world glycaemic outcomes in children with type 1 diabetes commencing advanced hybrid closed loop therapy and to explore these outcomes based on the cohort's clinical and socioeconomic characteristics.
Regular physical activity and exercise (PA) are cornerstones of diabetes care for individuals with type 1 diabetes. In recent years, the availability of automated insulin delivery (AID) systems has improved the ability of people with type 1 diabetes to achieve the recommended glucose target ranges. PA provide additional health benefits but can cause glucose fluctuations, which challenges current AID systems.
Globally, nearly 9 million people are living with type 1 diabetes (T1D). Although the incidence of T1D is not affected by socioeconomic status, the development of complications and limited access to modern therapy is overrepresented in vulnerable populations. Diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, are considered the gold standard for management of T1D, yet access to these technologies varies widely across countries and regions, and varies widely even within high-income countries.